Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.78 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680661 | 0.88 | HPGD (1.00) | HPGDSLC6A7MGLLNAMPTKDM4E | |
| SCHEMBL23680567 | 0.86 | HPGD (0.59) | HPGDMGLLVNN1MAPTKDM4E | |
| SCHEMBL23680549 | 0.85 | HPGD (0.59) | HPGDMGLLVNN1MAPT | |
| SCHEMBL23680595 | 0.82 | HPGD (0.54) | HPGDSLC6A7MAPTKDM4ETP53 | |
| SCHEMBL23675254 | 0.81 | HPGD (0.53) | HPGDSLC6A7KDM4ETP53L3MBTL1 | |
| SCHEMBL23680574 | 0.79 | HPGD (0.50) | HPGDSLC6A7VNN1NAMPTKDM4E | |
| SCHEMBL23680569 | 0.79 | HPGD (0.53) | HPGDMGLLVNN1MAPTL3MBTL1 | |
| SCHEMBL23680749 | 0.79 | HPGD (0.53) | HPGDMGLL | |
| SCHEMBL23680692 | 0.78 | HPGD (0.51) | HPGDMGLLVNN1L3MBTL1 | |
| SCHEMBL23680753 | 0.78 | HPGD (0.53) | HPGDMGLLVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885SLC6A7 922/4885MGLL 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.